Chemodex

Pemafibrate

Name: Pemafibrate
Brand: Chemodex
SKU: CDX-P0721
Price: 135.00 CHF
Availability: InStock

As low as CHF 135.00

In stock

Only %1 left

CDX-P0721-M01010 mgCHF 135.00

CDX-P0721-M05050 mgCHF 464.00

Specifications / Handling

More Information
Product Details
Synonyms	K877; (R)-K 13675; CS-2768
Product Type	Chemical
Properties
Formula	C₂₈H₃₀N₂O₆
MW	490.56
CAS	848259-27-8
Source/Host Chemicals	Synthetic
Purity Chemicals	≥98% (NMR)
Appearance	White to yellow solid.
Solubility	Soluble in DMSO (20mg/ml). Insoluble in water.
Identity	Determined by ¹H-NMR.
Declaration	Manufactured by Chemodex.
Other Product Data	Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet.
InChi Key	ZHKNLJLMDFQVHJ-RUZDIDTESA-N
Smiles	CC[C@H](C(O)=O)OC1=CC(CN(C2=NC3=C(C=CC=C3)O2)CCCOC4=CC=C(OC)C=C4)=CC=C1
Shipping and Handling
Shipping	AMBIENT
Short Term Storage	+4°C
Long Term Storage	+4°C
Handling Advice	Protect from light and moisture.
Use/Stability	Stable for at least 2 years after receipt when stored at +4°C.
Documents
Product Specification Sheet
Datasheet	Download PDF

Scientific Background Information

Product Description

Pemafibrate is a peroxisome proliferator-activated receptor α agonist (PPARα EC50 = 1nM for transcriptional activity). Pemafibrate is selective for PPARα over PPARδ and PPARγ (EC50 = 2300 and 1000nM, respectively). PPARα is a transcription factor that is essential for regulation of lipid homeostasis and glucose metabolism and has been implicated in inflammation. Pemafibrate was associated with the inhibition of inflammatory responses without affecting cell proliferation or angiogenesis, and subsequently may induce an anti-atherosclerotic effect.

Product-specific References

(1) K. Kitajima, et al.; Atheroscl. 203, 75 (2009) | (2) N. Hennuyer, et al.; Atheroscl. 249, 200 (2016) | (3) Y. Honda, et al.; Sci. Rep. 7, 42477 (2017) | (4) N. Ferri, et al.; Expert. Opin. Investig. Drugs 26, 593 (2017) | (5) J.C. Fruchart; Cardiovasc. Diabetol. 16, 124 (2017) | (6) Y. Yamamoto, et al.; Biochem. Biophys. Res. Commun. 499, 239 (2018) | (7) J.C. Fruchart & R.D. Santos; Curr. Opin. Lipidol. 30, 419 (2019) | (8) Y. Sasaki, et al.; Sci. Rep. 10, 7818 (2020)

Call	+41 61 926 6040
Fax	+41 61 926 6049